Class- and molecule-specific differential effects of angiotensin II type 1 receptor blockers

Current Pharmaceutical Design

Volumn 19, Issue 17, 2013, Pages 3002-3008

  Imaizumi, Satoshi ^a   Miura, Shin ichiro ^a,b   Yahiro, Eiji ^a   Uehara, Yoshinari ^a   Komuro, Issei ^c,d   Saku, Keijiro ^a  

^a FUKUOKA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b LERNER RESEARCH INSTITUTE   (United States)

^c OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^d UNIVERSITY OF TOKYO   (Japan)

Author keywords

Angiotensin II type receptor blocker; Cardiovascular disease; Class specific effects; Molecular structures; Molecule specific effects

Indexed keywords

2 BUTYL 4 CHLORO 1 [[2' (1H TETRAZOL 5 YL) 4 BIPHENYLYL]METHYL] 5 IMIDAZOLECARBOXYLIC ACID; ANGIOTENSIN 1 RECEPTOR; ANGIOTENSIN 1 RECEPTOR ANTAGONIST; AZILSARTAN; CANDESARTAN; EPROSARTAN; INTERCELLULAR ADHESION MOLECULE 1; IRBESARTAN; L SELECTIN; LOSARTAN; MONOCYTE CHEMOTACTIC PROTEIN 1; OLMESARTAN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; TELMISARTAN; VALSARTAN;

ANTIINFLAMMATORY ACTIVITY; ANTIOXIDANT ACTIVITY; BINDING AFFINITY; CARDIOVASCULAR DISEASE; DIABETIC NEPHROPATHY; DRUG CLASSIFICATION; DRUG EFFECT; DRUG MECHANISM; DRUG RECEPTOR BINDING; DRUG STRUCTURE; HUMAN; HYPERTENSION; NONHUMAN; PHARMACODYNAMICS; PRIORITY JOURNAL; REVIEW; STRUCTURE ACTIVITY RELATION; THROMBOCYTE AGGREGATION; URIC ACID BLOOD LEVEL;

ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANIMALS; ANTI-INFLAMMATORY AGENTS; ANTIOXIDANTS; CLINICAL TRIALS AS TOPIC; DIABETIC NEPHROPATHIES; DRUG INVERSE AGONISM; HUMANS; PLATELET AGGREGATION; PPAR GAMMA; RECEPTOR, ANGIOTENSIN, TYPE 1; URIC ACID;

EID: 84878630000     PISSN: 13816128     EISSN: 18734286     Source Type: Journal    
DOI: 10.2174/1381612811319170005     Document Type: Review

References (75)

1. Pierce KL, Premont RT, Lefkowitz RJ. Seven-transmembrane receptors. Nat Rev Mol Cell Biol 2002; 3: 639-50.
2. Dahlof B, Devereux RB, Kjeldsen SE, et al. Cardiovascular morbidity and mortality in the losartan intervention for endpoint reduction in hypertension study (life): A randomised trial against atenolol. Lancet 2002; 359: 995-1003.
3. Hoieggen A, Alderman MH, Kjeldsen SE, et al. The impact of serum uric acid on cardiovascular outcomes in the life study. Kidney Int 2004; 65: 1041-9.
4. Noda K, Saad Y, Kinoshita A, et al. Tetrazole and carboxylate groups of angiotensin receptor antagonists bind to the same subsite by different mechanisms. J Biol Chem 1995; 270: 2284-9.
5. Feng YH, Noda K, Saad Y, Liu XP, Husain A, Karnik SS. The docking of Arg2 of angiotensin II with Asp281 of AT1 receptor is essential for full agonism. J Biol Chem 1995; 270: 12846-50.
6. Noda K, Saad Y, Karnik SS. Interaction of Phe8 of angiotensin II with Lys199 and His256 of AT1 receptor in agonist activation. J Biol Chem 1995; 270: 28511-4.
7. Feng YH, Miura S, Husain A, Karnik SS. Mechanism of constitutive activation of the AT1 receptor: Influence of the size of the agonist switch binding residue Asn(111). Biochemistry 1998; 37: 15791-8.
8. Miura S, Feng YH, Husain A, Karnik SS. Role of aromaticity of agonist switches of angiotensin II in the activation of the AT1 receptor. J Biol Chem 1999; 274: 7103-10.
9. Timmermans PB, Wong PC, Chiu AT, et al. Angiotensin II receptors and angiotensin II receptor antagonists. Pharmacol Rev 1993; 45: 205-51.
10. Miura S, Okabe A, Matsuo Y, Karnik SS, Saku K. Unique binding behavior of the recently approved angiotensin II receptor blocker azilsartan compared to that of candesartan. Hypertens Res 2012. (in press)
11. Zhang J, Pfaffendorf M, Zhang JS, Van Zwieten PA. A noncompetitive type of angiotensin-receptor antagonism by losartan in renal artery preparations. Eur J Pharmacol 1994; 252: 337-40.
12. Zaiken K, Cheng JW. Azilsartan medoxomil: A new angiotensin receptor blocker. Clin Ther 2011; 33: 1577-89.
13. Munger MA. Use of angiotensin receptor blockers in cardiovascular protection: Current evidence and future directions. P T 2011; 36: 22-40.
14. Miura S, Saku K. Efficacy and safety of angiotensin II type 1 receptor blocker/calcium channel blocker combination therapy: focus on a single-pill fixed-dose combination of valsartan/amlodipine. J Int Med Res 2012; 40: 1-9.
15. Awad AS, Webb RL, Carey RM, Siragy HM. Renal nitric oxide production is decreased in diabetic rats and improved by AT1 receptor blockade. J Hypertens 2004; 22: 1571-7.
16. Miura S, Karnik SS, Saku K. Angiotensin II type 1 receptor blockers: Class effects vs. Molecular effects. J Renin Angiotensin Aldosterone Syst 2011; 12: 1-7.
17. Tuccinardi T, Calderone V, Rapposelli S, Martinelli A. Proposal of a new binding orientation for non-peptide AT1 antagonists: Homology modeling, docking and three-dimensional quantitative structure-activity relationship analysis. J Med Chem 2006; 49: 4305-16.
18. 1receptordependent and-independent beneficial effects. Hypertens Res 2010; 33: 1044-52.
19. Miura S, Kiya Y, Kanazawa T, et al. Differential bonding interactions of inverse agonists of angiotensin II type 1 receptor in stabilizing the inactive state. Mol Endocrinol 2008; 22: 139-46.
20. Seifert R, Wenzel-Seifert K. Constitutive activity of G-proteincoupled receptors: Cause of disease and common property of wildtype receptors. Naunyn Schmiedebergs Arch Pharmacol 2002; 366: 381-416.
21. Spiegel AM. Defects in G protein-coupled signal transduction in human disease. Annu Rev Physiol 1996; 58: 143-70.
22. Parma J, Duprez L, Van Sande J, et al. Somatic mutations in the thyrotropin receptor gene cause hyperfunctioning thyroid adenomas. Nature 1993; 365: 649-51.
23. Yasuda N, Akazawa H, Ito K, et al. Agonist-independent constitutive activity of angiotensin II receptor promotes cardiac remodeling in mice. Hypertension 2012; 59: 627-33.
24. Kijima K, Matsubara H, Murasawa S, et al. Mechanical stretch induces enhanced expression of angiotensin II receptor subtypes in neonatal rat cardiac myocytes. Circ Res 1996; 79: 887-97.
25. Xu ZG, Lanting L, Vaziri ND, et al. Upregulation of angiotensin II type 1 receptor, inflammatory mediators, and enzymes of arachidonate metabolism in obese Zucker rat kidney: reversal by angiotensin II type 1 receptor blockade. Circulation 2005; 111: 1962-9.
26. Palczewski K, Kumasaka T, Hori T, et al. Crystal structure of rhodopsin: A G protein-coupled receptor. Science 2000; 289: 739-45.
27. Scheerer P, Park JH, Hildebrand PW, et al. Crystal structure of opsin in its G-protein-interacting conformation. Nature 2008; 455: 497-502.
28. Park JH, Scheerer P, Hofmann KP, Choe HW, Ernst OP. Crystal structure of the ligand-free G-protein-coupled receptor opsin. Nature 2008; 454: 183-7.
29. Cherezov V, Rosenbaum DM, Hanson MA, et al. High-resolution crystal structure of an engineered human beta2-adrenergic G protein-coupled receptor. Science 2007; 318: 1258-65.
30. Rosenbaum DM, Cherezov V, Hanson MA, et al. GPCR engineering yields high-resolution structural insights into beta2-adrenergic receptor function. Science 2007; 318: 1266-73.
31. Rosenbaum DM, Zhang C, Lyons JA, et al. Structure and function of an irreversible agonist-beta(2) adrenoceptor complex. Nature 2011; 469: 236-40.
32. Rasmussen SG, Choi HJ, Fung JJ, et al. Structure of a nanobodystabilized active state of the beta(2) adrenoceptor. Nature 2011; 469: 175-80.
33. Warne T, Moukhametzianov R, Baker JG, et al. The structural basis for agonist and partial agonist action on a beta(1)-adrenergic receptor. Nature 2011; 469: 241-4.
34. Martin SS, Boucard AA, Clement M, Escher E, Leduc R, Guillemette G. Analysis of the third transmembrane domain of the human type 1 angiotensin II receptor by cysteine scanning mutagenesis. J Biol Chem 2004; 279: 51415-23.
35. Miura S, Kiya Y, Hanzawa H, et al. Small molecules with similar structures exhibit agonist, neutral antagonist or inverse agonist activity toward angiotensin II type 1 receptor. PLoS One 2012; 7: e37974.
36. Zou Y, Akazawa H, Qin Y, et al. Mechanical stress activates angiotensin II type 1 receptor without the involvement of angiotensin II. Nat Cell Biol 2004; 6: 499-506.
37. Akazawa H, Yasuda N, Komuro I. Mechanisms and functions of agonist-independent activation in the angiotensin II type 1 receptor. Mol Cell Endocrinol 2009; 302: 140-7.
38. Komuro I, Yazaki Y. Control of cardiac gene expression by mechanical stress. Annu Rev Physiol 1993; 55: 55-75.
39. Gruden G, Thomas S, Burt D, et al. Interaction of angiotensin II and mechanical stretch on vascular endothelial growth factor production by human mesangial cells. J Am Soc Nephrol 1999; 10: 730-7.
40. Ogawa S, Mori T, Nako K, Kato T, Takeuchi K, Ito S. Angiotensin II type 1 receptor blockers reduce urinary oxidative stress markers in hypertensive diabetic nephropathy. Hypertension 2006; 47: 699-705.
41. Cianchetti S, Del Fiorentino A, Colognato R, Di Stefano R, Franzoni F, Pedrinelli R. Anti-inflammatory and anti-oxidant properties of telmisartan in cultured human umbilical vein endothelial cells. Atherosclerosis 2008; 198: 22-8.
42. Takai S, Kirimura K, Jin D, et al. Significance of angiotensinII receptor blocker lipophilicities and their protective effect against vascular remodeling. Hypertens Res 2005; 28: 593-600.
43. Proudfoot JM, Croft KD, Puddey IB, Beilin LJ. Angiotensin II type 1 receptor antagonists inhibit basal as well as low-density lipoprotein and platelet-activating factor-stimulated human monocyte chemoattractant protein-1. J Pharmacol Exp Ther 2003; 305: 846-53.
44. Marshall TG, Lee RE, Marshall FE. Common angiotensin receptor blockers may directly modulate the immune system via VDR, PPAR and CCR2b. Theor Biol Med Model 2006; 3: 1.
45. Alderman MH. Uric acid and cardiovascular risk. Curr Opin Pharmacol 2002; 2: 126-30.
46. Sica DA, Schoolwerth AC. Part 1. Uric acid and losartan. Curr Opin Nephrol Hypertens 2002; 11: 475-82.
47. Iwanaga T, Sato M, Maeda T, Ogihara T, Tamai I. Concentrationdependent mode of interaction of angiotensin II receptor blockers with uric acid transporter. J Pharmacol Exp Ther 2007; 320: 211-7.
48. Huang JV, Greyson CR, Schwartz GG. PPAR-γ as a therapeutic target in cardiovascular disease: evidence and uncertainty: Thematic Review Series: New Lipid and Lipoprotein Targets for the Treatment of Cardiometabolic Diseases. J Lipid Res 2012; 53: 1738-54.
49. Schupp M, Janke J, Clasen R, Unger T, Kintscher U. Angiotensin type 1 receptor blockers induce peroxisome proliferator-activated receptor-gamma activity. Circulation 2004; 109: 2054-7.
50. Clasen R, Schupp M, Foryst-Ludwig A, et al. PPARgammaactivating angiotensin type-1 receptor blockers induce adiponectin. Hypertension 2005; 46: 137-43.
51. Benson SC, Pershadsingh HA, Ho CI, et al. Identification of telmisartan as a unique angiotensin II receptor antagonist with selective PPARgamma-modulating activity. Hypertension 2004; 43: 993-1002.
52. Furuhashi M, Ura N, Higashiura K, et al. Blockade of the reninangiotensin system increases adiponectin concentrations in patients with essential hypertension. Hypertension 2003; 42: 76-81.
53. Koh KK, Quon MJ, Han SH, et al. Additive beneficial effects of losartan combined with simvastatin in the treatment of hypercholesterolemic, hypertensive patients. Circulation 2004; 110: 3687-92.
54. Haller H, Ito S, Izzo JL Jr, et al. Olmesartan for the delay or prevention of microalbuminuria in type 2 diabetes. N Engl J Med 2011; 364: 907-17.
55. Rossing K, Christensen PK, Andersen S, Hovind P, Hansen HP, Parving HH. Comparative effects of irbesartan on ambulatory and office blood pressure: A substudy of ambulatory blood pressure from the irbesartan in patients with type 2 diabetes and microalbuminuria study. Diabetes Care 2003; 26: 569-74.
56. Brenner BM, Cooper ME, de Zeeuw D, et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001; 345: 861-9.
57. Bilous R, Chaturvedi N, Sjolie AK, et al. Effect of candesartan on microalbuminuria and albumin excretion rate in diabetes: Three randomized trials. Ann Intern Med 2009;151:11-20, W3-4.
58. Chopicki S, Koda M, Chabielska E, Buczko W, Gryglewski RJ. Antiplatelet action of losartan involves TXA2 receptor antagonism but not TXA2 synthase inhibition. J Physiol Pharmacol 2000; 51(4 Pt 1): 715-22.
59. Jiménez AM, Montón M, García R, et al. Inhibition of platelet activation in stroke-prone spontaneously hypertensive rats: comparison of losartan, candesartan, and valsartan. J Cardiovasc Pharmacol 2001; 37: 406-12.
60. Oparil S, Williams D, Chrysant SG, Marbury TC, Neutel J. Comparative efficacy of olmesartan, losartan, valsartan, and irbesartan in the control of essential hypertension. J Clin Hypertens (Greenwich) 2001; 3: 283-91.
61. Fogari R, Mugellini A, Zoppi A, Derosa G. Efficacy of losartan, valsartan, and telmisartan in patients with mild to moderate hyper tension: A double-blind, placebo-controlled, crossover study using ambulatory blood pressure monitoring. Curr Ther Res 2002; 63: 1-14.
62. Rakugi H, Enya K, Sugiura K, Ikeda Y. Comparison of the efficacy and safety of azilsartan with that of candesartan cilexetil in Japanese patients with grade I-II essential hypertension: a randomized, double-blind clinical study. Hypertens Res 2012; 35: 552-8.
63. Lewington S, Clarke R, Qizilbash N, Peto R, Collins R; Prospective Studies Collaboration. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet 2002; 360: 1903-13.
64. Koh KK, Han SH, Chung WJ, et al. Comparison of effects of losartan, irbesartan, and candesartan on flow-mediated brachial artery dilation and on inflammatory and thrombolytic markers in patients with systemic hypertension. Am J Cardiol 2004; 93: 1432-5, A1410.
65. Iwata A, Miura S, Imaizumi S, et al. Do valsartan and losartan have the same effects in the treatment of coronary artery disease? Circ J 2007; 71: 32-8.
66. Picca M, Agozzino F, Pelosi G. Effects of losartan and valsartan on left ventricular hypertrophy and function in essential hypertension. Adv Ther 2004; 21: 76-86.
67. Sugihara M, Miura S, Takamiya Y, et al. Safety and efficacy of antihypertensive therapy with add-on angiotensin II type 1 receptor blocker after successful coronary stent implantation. Hypertens Res 2009; 32: 625-30.
68. Tsutamoto T, Nishiyama K, Yamaji M, et al. Comparison of the long-term effects of candesartan and olmesartan on plasma angiotensin II and left ventricular mass index in patients with hypertension. Hypertens Res 2010; 33: 118-22.
69. Pantev E, Stenman E, Wackenfors A, Edvinsson L, Malmsjo M. Comparison of the antagonistic effects of different angiotensin II receptor blockers in human coronary arteries. Eur J Heart Fail 2002; 4: 699-705.
70. Elliott WJ, Calhoun DA, DeLucca PT, Gazdick LP, Kerns DE, Zeldin RK. Losartan versus valsartan in the treatment of patients with mild to moderate essential hypertension: Data from a multicenter, randomized, double-blind, 12-week trial. Clin Ther 2001; 23: 1166-79.
71. Wurzner G, Gerster JC, Chiolero A, et al. Comparative effects of losartan and irbesartan on serum uric acid in hypertensive patients with hyperuricaemia and gout. J Hypertens 2001; 19: 1855-60.
72. Yamada S, Ano N, Toda K, et al. Telmisartan but not candesartan affects adiponectin expression in vivo and in vitro. Hypertens Res 2008; 31: 601-6.
73. Morii J, Miura S, Shiga Y, et al. Comparison of the efficacy and safety of irbesartan and olmesartan in patients with hypertension (Earth study). Clin Exp Hypertens 2012; 34: 342-9.
74. Núñez A, Gómez J, Zalba LR, et al. Losartan inhibits in vitro platelet activation: comparison with candesartan and valsartan. J Renin Angiotensin Aldosterone Syst 2000; 1: 175-9.
75. Sato Y, Fujii S, Imagawa S, et al. Platelet aggregability in patients with hypertension treated with angiotensin II type 1 receptor blockers. J Atheroscler Thromb 2007; 14: 31-5.